Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Aptámeros multifuncionales para el tratamiento y diagnóstico del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20140923002
Publicado:
07/09/2015
Caducidad:
23/03/2016
Resumen:
Una universidad alemana ofrece nuevos aptámeros como productos terapéuticos y de diagnóstico de amplio espectro para el tratamiento del cáncer. Los aptámeros reconocen células tumorales específicas sin afectar a las células sanas. Además pueden administrar sustancias macromoleculares en células tumorales. Al no ser tóxicos, están indicados para aplicaciones biomédicas. El diagnóstico y tratamiento de varios tipos de tumores con una sola formulación reducen los costes de desarrollo de productos farmacéuticos. La universidad busca licenciatarios.

Details

Tittle:
Multifunctional aptamers for the treatment and diagnosis of cancer
Summary:
A German university offers new aptamers as novel broad spectrum therapeutics and diagnostics for the treatment of cancer. Aptamers specifically recognize tumour cells without affecting healthy cells. Furthermore they can deliver macromolecular molecules into tumour cells. As they are non-toxic, they may well be suitable for biomedical applications. Licensees are sought.
Description:
Targeted therapy has become a promising therapeutic approach within the last decade due to its reduced toxicity. However, further development of targeted approaches for the specific delivery of therapeutically active substances is required. The targeted delivery of macromolecular charged drug-like molecules, e.g. antagomirs and siRNA, is limited since these candidates do not cross cell membranes but rather have to be actively provided to the intracellular milieu.

The present invention of a German university provides novel aptamers capable of recognizing tumour cells and delivering macromolecular molecules into tumour cells. Diagnosis and treatment of several tumour types with one formulation reduces the developing costs for pharmaceuticals.
Aptamers are short single-stranded nucleic acids that recognize specific target structures with high affinity and specificity. Since aptamers have been shown to possess almost no toxicity and immunogenicity they are promising candidates for biomedical applications.

The identified aptamers recognize various cancer cells particularly those derived from solid tumours, while non-tumourgenic and primary healthy cells are not recognized.
These findings render the aptamers applicable as broad-spectrum diagnostics and therapeutics.

Industrial licensees are sought.

Advantages and Innovations:
· The described technology enables diagnosis and treatment of several tumour types with one formulation, thereby reducing the developing costs for pharmaceuticals
· Non-toxic
· Suitable for the specific delivery of macromolecular molecules
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European patent pending

Partner sought

Type and Role of Partner Sought:
Licensees from pharmaceutical industry are sought.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos